Ultra-Rare Immune System Disease Gets First FDA-Approved Treatment
The FDA approved pozelimab (Veopoz) as the first treatment for adults and children ages 1 year and up with CD55-deficient protein-losing enteropathy. Also known as CHAPLE (complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy) disease, CD55-deficient protein-losing enteropathy is an inherited disease marked by mutations of the complement regulator CD55 gene, which causes the complement system […]